Ra Pharmaceuticals
Pharmaceutical ManufacturingMassachusetts, United States5001-10000 Employees
On April 2, 2020, Ra Pharmaceuticals, Inc. was acquired by UCB. For more information, please visit www.linkedin.com/company/ucb-pharma.
Recent Expansions Recent expansions into innovative therapies such as single-injection bimekizumab and initiatives like the FASTRAX program present sales opportunities in the rheumatology and neurology sectors.
Market Presence Attendance at major international conferences and events like the MGFA International Conference and AD/PD Congress showcases a strong market presence, indicating potential for global sales and collaborations.
Strategic Asset Sales Successful asset sales, like the recent divestment to Cbridgecap for $680M, demonstrate a focus on optimizing business portfolio, potentially freeing up resources for new ventures and strategic partnerships.
Technology Integration Utilization of cutting-edge technologies like SAP SuccessFactors and IBM Spectrum LSF signifies a commitment to efficiency and innovation, offering opportunities for tech-based sales solutions and collaborations.
Financial Health Strong revenue in the range of $100M - 1B, coupled with substantial funding of $150M, indicates financial stability and growth potential, creating a favorable environment for sales negotiations and investments.
Ra Pharmaceuticals uses 8 technology products and services including theTradeDesk, SAP SuccessFactors, OneDrive, and more. Explore Ra Pharmaceuticals's tech stack below.
Ra Pharmaceuticals Email Formats | Percentage |
FLast@rapharma.com | 86% |
First-L@rapharma.com | 2% |
F_Last@rapharma.com | 2% |
Last_First@rapharma.com | 2% |
First_L@rapharma.com | 2% |
FirLast@rapharma.com | 1% |
FirstLast@rapharma.com | 2% |
LFirst@rapharma.com | 1% |
First@rapharma.com | 1% |
F.Last@rapharma.com | 1% |
First.Last@ucb.com | 93% |
FLast@ucb.com | 5% |
First@ucb.com | 1% |
Last.First@ucb.com | 1% |
Pharmaceutical ManufacturingMassachusetts, United States5001-10000 Employees
On April 2, 2020, Ra Pharmaceuticals, Inc. was acquired by UCB. For more information, please visit www.linkedin.com/company/ucb-pharma.
Ra Pharmaceuticals has raised a total of $150M of funding over 4 rounds. Their latest funding round was raised on Jul 29, 2019 in the amount of $150M.
Ra Pharmaceuticals's revenue is in the range of $100M$1B
Ra Pharmaceuticals has raised a total of $150M of funding over 4 rounds. Their latest funding round was raised on Jul 29, 2019 in the amount of $150M.
Ra Pharmaceuticals's revenue is in the range of $100M$1B